Investment
Features
FeesSafety
Academy
More
Pluang+

Compare General Dynamics Corporation (GD) vs Invesco Ltd. (IVZ) Price & Performance

General Dynamics CorporationTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

General Dynamics Corporation vs Invesco Ltd. — how do they compare? General Dynamics Corporation trades at $392 (market cap $106.03B), while Invesco Ltd. trades at $31.45 (market cap $13.85B). The key difference: General Dynamics Corporation is far larger — about 7.7× Invesco Ltd.'s market cap, and Invesco Ltd. pays the higher dividend (2.74%). Which is the better fit depends on your goals.

GDIVZ
Market Cap
$106.03B$13.85B
Sector
IndustrialsFinancials
52-Week High
$395.97$32.01
52-Week Low
$312.53$20.67
Enterprise Value
$111.17B$24.01B
Dividend Yield
1.62%2.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

General Dynamics Corporation

General Dynamics (GD) trades at $394.17, down 0.45% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.24 beating estimates, revenue growth to $52.55B in 2025, and improving profit margins. Recent contract wins include a $29.5B submarine award and a $1.3B Army cybersecurity contract, supporting the $136.5B backlog.

Outlook remains positive with analyst consensus target of $427.40 representing 8.4% upside potential. Key opportunities include defense budget tailwinds and strong contract pipeline, while risks involve valuation concerns at 23.9 P/E and execution challenges on large government contracts. The stock offers steady dividend payments with recent $1.59 quarterly declaration.

Invesco Ltd.

Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.

The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About General Dynamics Corporation

General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.

Read more on GD

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ